Illumina Inc, founded in 1998 and headquartered in San Diego, California, is a pioneering biotechnology company focused on improving human health by unlocking the power of the genome. The company's primary offerings include advanced sequencing and genomic analysis technologies that enable researchers and clinicians to analyze genetic information efficiently and accurately.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| ILMN 2.55% 2031-03-23 USDIllumina Inc | United States | 2031-03-23 | 2.550 | 4.87 |
| ILMN 4.75% 2030-12-12 USDIllumina Inc | United States | 2030-12-12 | 4.750 | 4.93 |
| ILMN 5.75% 2027-12-13 USDIllumina Inc | United States | 2027-12-13 | 5.750 | 4.45 |
| ILMN 5.80% 2025-12-12 USDIllumina Inc | United States | 2025-12-12 | 5.800 | 0.00 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Illumina began issuing bonds in 2015 to support its strategic growth and acquisitions, with notable issuances including a $1 billion offering in 2021 to finance the acquisition of Grail, a multi-cancer early detection company. The bond yields for Illumina's issuances have generally remained competitive within the biotechnology sector, with recent yields in the range of 2.5% to 3.5%. In 2023, the company’s bonds gained attention for their sustainability features, reflecting Illumina's commitment to innovation in both its products and corporate responsibility.